Bioharvest Sciences Inc. BHST
Annual
Quarterly
FY2025 · ended Dec 31, 2025 · Revenue $34.51M, +37.0% YoY · Filed Mar 31, 2026
Bioharvest Sciences Inc. (BHST) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $34.5 million and a net loss of $11.1 million. Free cash flow was -$9.6 million. As of Dec 31, 2025 it held $23.0 million in cash and investments and $10.3 million in total debt.
Revenue
$34.51M
+37.0% vs prior year
Net income
$-11.13M
+13.8% vs prior year
Operating cash flow
$-7.23M
-8.1% vs prior year
Free cash flow
$-9.58M
-0.7% vs prior year
EPS
—
Dividend per share
None
Shares outstanding
22.67M
+30.8% vs prior year
Net cash
$12.75M
FY 2025
Operating margin
-16.2%
FY 2025
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- BHST (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- British Columbia, Canada
- Headquarters
- Vancouver, British Columbia, Canada
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1723464
- Former names
- CANNA-V-CELL SCIENCES INC. (until Apr 21, 2020); Midnight Star Ventures Corp. (until Oct 15, 2018)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
|---|---|---|
| Revenue | $34.5M | $25.2M |
| Operating income | -$5.6M | -$7.0M |
| Net income | -$11.1M | -$12.9M |
| Operating cash flow | -$7.2M | -$6.7M |
| Free cash flow | -$9.6M | -$9.5M |
| Total assets | $47.7M | $25.0M |
| Stockholders' equity | $25.4M | $1.3M |
| Cash and investments | $23.0M | $2.4M |
| Total debt | $10.3M | $13.0M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 6-K | Current report (foreign issuer) | Oct 29, 2026 | Oct 29, 2026 |
| 6-K | Current report (foreign issuer) | Oct 13, 2026 | Oct 13, 2026 |
| 6-K | Current report (foreign issuer) | Oct 8, 2026 | Oct 8, 2026 |
| 6-K | Current report (foreign issuer) | Oct 2, 2026 | Oct 1, 2026 |
| 6-K | Current report (foreign issuer) | Sep 15, 2026 | Sep 15, 2026 |
| 6-K | Current report (foreign issuer) | Sep 15, 2026 | Sep 15, 2026 |
All 136 Bioharvest Sciences Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.